Skip to main content

Table 1 Base-line characteristics of the 475 subjects and results of serum testing

From: Diagnostic value of immunoglobulin G antibodies against Candida enolase and fructose-bisphosphate aldolase for candidemia

 

Number [anti-Eno (%) positive; anti-Fba1(%) positive]

  

Control group

Characteristic

Patients with candidemia

Patients with candida colonization

Patients with bacteremia

Patients with IAa

Healthy subjects

 

n = 101

n = 50

n = 84

n = 40

n = 200

Demographic factors

     

 Sex

     

  Male

63 (73.0, 82.5)f

41 (7.3; 7.3)

52 (3.8,19.2)

33 (6.1; 0)

117 (2.6; 5.1)

  Female

38 (71.1, 94.7)

9 (22.2; 22.2)

32 (6.3; 9.4)

7 (14.3; 14.3)

83 (1.2; 2.4)

 Age (years, mean ± SD)

52.3 ± 19.6

76.12 ± 14.89

51.9 ± 14.2

57.6 ± 15.8

59.1 ± 12.4

  ≤65 years

71 (69.0, 87.3)g

9 (22.2; 44.4)

48 (6.3; 14.6)

28 (3.6; 0)

108 (1.9; 4.6)

  >65 years

30 (80.0, 86.7)

41 (7.3; 2.4)

36 (2.8; 16.7)

12 (16.7; 8.3)

92 (2.2; 3.3)

Primary condition

     

 Hematological malignancy

10 (60.0; 80.0)

3 (33.3; 33.3)

6 (33.3; 33.3)

1 (0; 0)

0

  Leukemia

5 (40.0; 80.0)

1 (0; 0)

3 (33.3; 33.3)

  

  Lymphoma

3 (100.0; 66.7)

1 (100.0; 100.0)

2 (50.0; 50.0)

  

  Myelodysplasia

1 (0; 100.0)

1 (0; 0)

1 (0; 0)

  

  Multiple myeloma

1 (100.0; 100.0)

0 (0; 0)

0 (0; 0)

1 (0; 0)

 

 Solid tumor

11 (45.5; 81.8)

7 (14.3; 28.6)

10 (0; 30.0)

0

0

  Bronchopulmonary neoplasm

2 (50.0; 50.0)

1 (0; 0)

4 (0; 50.0)

  

  Pancreas/colon adenocarcinoma

7 (71.4; 85.7)

6 (16.7; 33.3)

5 (0; 20)

  

  Bladder neoplasm

2 (50.0; 100.0)

0 (0; 0)

1 (0; 0)

  

 Nonmalignant diseases

80 (77.5; 88.8)

40 (7.5; 5.0)

68 (2.9; 11.8)

39 (7.7; 2.6)

0

  Respiratory dysfunctionb

5 (80.0; 60.0)

18 (11.1; 5.6)

3 (33.3; 33.3)

21 (4.8; 4.8)

 

  Gastrointestinal pathologyc

65 (75.4; 92.3)

4 (25.0; 25.0)

60 (1.7; 11.7)

2 (100.0; 0)

 

  Othersd

10 (90.0; 80.0)

18 (0; 0)

5 (0; 0)

16 (0; 0)

 

Risk factors

     

 Iatrogenic predisposing factors

     

  Broad spectrum antibiotics

68 (76.5; 86.8)h

44 (4.5; 2.3)

64 (4.7; 9.4)

20 (5.0; 5.0)

0

  Glucocorticoids therapy

57 (87.7; 91.2)

40 (2.5; 2.5)

46 (2.2; 2.2)

0 (0; 0)

0

  Central venous catheters

36 (72.2; 88.9)

28 (0; 0)

27 (0; 0)

9 (0; 0)

0

  Parenteral nutrition

56 (82.1; 92.9)

15 (0; 0)

49 (0; 0)

3 (66.7; 0)

0

Other risk factors

     

  Intensive care unit stay

26 (80.8; 92.3)i

12 (8.3; 16.7)

18 (5.6; 11.1)

12 (16.7; 0)

0

 Neutropeniae

11 (36.4; 45.5)

2 (0; 50.0)

3 (0; 33.3)

0 (0; 0)

0

 Acute renal failure

2 (50.0; 50.0)

2 (50.0; 0)

1 (100.0; 0)

0 (0; 0)

0

Outcome of hospital stay

     

  Death

36 (63.9; 88.9)j

8 (37.5; 50.0)

10 (20.0; 50.0)

12 (8.3; 8.3)1,1

nk

  Discharge

65 (76.9; 86.2)

42 (4.8; 2.4)

74 (2.7; 10.8)

28 (7.1; 0)

nk

  1. a Patients with proven and probable IA.
  2. bIncludes the following diseases: pneumonia, chronic obstructive pulmonary disease, and acute respiratory distress syndrome.
  3. c Includes the following diseases: cholecystitis, angiocholitis, pancreatitis, peritonitis, and hepatitis.
  4. d Includes the following diseases: multiple trauma, acute renal insufficiency, and diabetes mellitus.
  5. e Neutropenia was defined as an absolute neutrophil count below 500 cells/mm3.
  6. f,g,h,I,j No significant difference was found in patients with candidemia associated with age, sex, predisposing factors for IC and clinical outcomes (P > 0.05).
  7. k Not applicable.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us